BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer

September 11, 2014 BioTime, Inc. announced that its subsidiary Asterias Biotherapeutics, Inc. has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialization arm, to conduct a clinical trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer. AST-VAC2 is a non-patient specific (allogeneic) cancer vaccine designed to stimulate patients’ immune …

Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax

Animal Studies Demonstrate Efficacy in Treatment of Non-Small Cell Lung Cancer May 23, 2014 Batu Biologics, a biopharmaceutical company focused on the development and commercialization of cell therapies in the area of immune modulation, is pleased to announce the filing of U.S. patent application (61/987657) covering the composition and application of its flagship product, Vallovax. The novel cancer vaccine is …

GSK Gives Up On Flagship Cancer Vaccine MAGE-A3

Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer April 2, 2014 GlaxoSmithKline plc today announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC …

Potential Lung Cancer Vaccine Shows Renewed Promise

March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an …